Attenuation of colistin bactericidal activity by high inoculum of pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2051-2062

  Bulitta, Jürgen B ^a,b   Yang, Jenny C ^a,e   Yohonn, Liliana ^a,c   Ly, Neang S ^a   Brown, Silvia V ^a   D'Hondt, Rebecca E ^b   Jusko, William J ^a   Forrest, Alan ^a   Tsuji, Brian T ^a,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; COLISTIN; MAGNESIUM ION;

ARTICLE; ATTENUATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMPUTER PROGRAM; CONTROLLED STUDY; IN VITRO STUDY; INHIBITION KINETICS; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BINDING, COMPETITIVE; CALCIUM; COLISTIN; DRUG RESISTANCE, BACTERIAL; MAGNESIUM; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA;

EID: 77951247743     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00881-09     Document Type: Article

References (74)

1. Adler, J. L., and M. Finland. 1971. Susceptibility of recent isolates of Pseudomonas aeruginosa to gentamicin, polymyxin, and five penicillins, with observations on the pyocin and immunotypes of the strains. Appl. Microbiol. 22:870-875.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
3. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
4. Aoki, N., K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi. 2009. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother. 63:534-542.
5. Bauer, R. J. 2008. S-ADAPT/MCPEM user's guide (version 1.56). Software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Berkeley, CA.
6. Beal, S. L. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
7. Beal, S. L., L. B. Sheiner, and A. J. Boeckmann. 2006. NONMEM users guides (1989-2006). Icon Development Solutions, Ellicott City, MD.
8. Bergen, P. J., J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642.
9. Brook, I. 1989. Inoculum effect. Rev. Infect. Dis. 11:361-368.
10. Bulitta, J. B., N. S. Ly, J. C. Yang, A. Forrest, W. J. Jusko, and B. T. Tsuji. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:46-56.
11. Bulitta, J. B., J. C. Yang, B. T. Tsuji, W. J. Jusko, and A. Forrest. 2007. Mechanistic PK/PD models for the inoculum effect (over 5 orders of magnitude) of colistin and ceftazidime against Pseudomonas aeruginosa (PA), poster W4553 (abstr. 1829). AAPS Annual Meeting, San Diego, CA, 11 to 15 November 2007.
12. Cerny, G., and M. Teuber. 1972. Comparative polyacrylamide electrophoresis of periplasmic proteins released from gram-negative bacteria by polymyxin B. Arch. Mikrobiol. 82:361-370.
13. Chen, C. C., and D. S. Feingold. 1972. Locus of divalent cation inhibition of the bactericidal action of polymyxin B. Antimicrob. Agents Chemother. 2:331-335.
14. Conrad, R. S., and C. Galanos. 1989. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob. Agents Chemother. 33:1724-1728.
15. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
16. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
17. Davis, S. D. 1975. Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 8:50-53.
18. Diggle, S. P., K. Winzer, S. R. Chhabra, K. E. Worrall, M. Camara, and P. Williams. 2003. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol. Microbiol. 50:29-43.
19. Dixon, R. A., and I. Chopra. 1986. Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide. Antimicrob. Agents Chemother. 29:781-788.
20. Donabedian, H. 2003. Quorum sensing and its relevance to infectious diseases. J. Infect. 46:207-214.
21. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
22. Drusano, G. L. 2007. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Infect. Dis. 45(Suppl. 1):S89-S95.
23. Dudhani, R. V., J. Li, and R. L. Nation. 2009. Plasma binding (PB) of colistin (C) involves multiple proteins and is concentration dependent: potential clinical implications, abstr. A1-576. Abstr. 49th Annu. Intersci. Conf. Antimicrob. Agents Chemotherapy. American Society for Microbiology, Washington, DC.
24. Dudley, M. N., H. D. Mandler, D. Gilbert, J. Ericson, K. H. Mayer, and S. H. Zinner. 1987. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. Am. J. Med. 82:363-368.
25. Eagle, H. 1949. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J. Exp. Med. 90:595-607.
26. Escartin, P., J. A. Rodriguez-Montes, V. Cuervas-Mons, I. Rossi, J. Alvarez-Cienfuegos, P. Maganto, and J. L. Castillo-Olivares. 1982. Effect of colistin on reduction of biliary flow induced by endotoxin in E. coli. Dig. Dis. Sci. 27:875-879.
27. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
28. Garcia-Medina, R., W. M. Dunne, P. K. Singh, and S. L. Brody. 2005. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect. Immun. 73:8298-8305.
29. Gardiner, K. R., P. J. Erwin, N. H. Anderson, M. D. McCaigue, M. I. Halliday, and B. J. Rowlands. 1995. Lactulose as an antiendotoxin in experimental colitis. Br. J. Surg. 82:469-472.
30. Gooderham, W. J., M. Bains, J. B. McPhee, I. Wiegand, and R. E. Hancock. 2008. Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PsrA in Pseudomonas aeruginosa. J. Bacteriol. 190:5624-5634.
31. Gunderson, B. W., K. H. Ibrahim, L. B. Hovde, T. L. Fromm, M. D. Reed, and J. C. Rotschafer. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:905-909.
32. Hancock, R. E. 2005. Mechanisms of action of newer antibiotics for Grampositive pathogens. Lancet Infect. Dis. 5:209-218.
33. Hancock, R. E., and D. S. Chapple. 1999. Peptide antibiotics. Antimicrob. Agents Chemother. 43:1317-1323.
34. Harigaya, Y., J. B. Bulitta, A. Forrest, G. Sakoulas, A. J. Lesse, J. M. Mylotte, and B. T. Tsuji. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53:3894-3901.
35. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
36. Kwon, D. H., and C. D. Lu. 2006. Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 50:1615-1622.
37. Landersdorfer, C. B., M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sorgel, and J. Gusinde. 2009. Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Antimicrob. Agents Chemother. 53:2569-2578.
38. 7 CFU in opposite thighs. Abstr. 47th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), abstr. A-37. American Society for Microbiology, Washington, DC.
39. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
40. Li, J., R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner, and D. L. Paterson. 2006. Colistin: the emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
41. Li, J., J. Turnidge, R. Milne, R. L. Nation, and K. Coulthard. 2001. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:781-785.
42. Linden, P. K., S. Kusne, K. Coley, P. Fontes, D. J. Kramer, and D. Paterson. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37:e154-e160.
43. Loh, B., C. Grant, and R. E. Hancock. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551.
44. Louie, A., H. S. Heine, K. Kim, D. L. Brown, B. VanScoy, W. Liu, M. Kinzig-Schippers, F. Sorgel, and G. L. Drusano. 2008. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52:2486-2496.
45. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48:2061-2068.
46. Mestres, C., M. A. Alsina, M. A. Busquets, I. Muranyi, and F. Reig. 1998. Interaction of colistin with lipids in liposomes and monolayers. Int. J. Pharm. 160:99-107.
47. Mizunaga, S., T. Kamiyama, Y. Fukuda, M. Takahata, and J. Mitsuyama. 2005. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J. Antimicrob. Chemother. 56:91-96.
48. Moore, R. A., N. C. Bates, and R. E. Hancock. 1986. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob. Agents Chemother. 29:496-500.
49. Moskowitz, S. M., R. K. Ernst, and S. I. Miller. 2004. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186:575-579.
50. Mouton, J. W., A. A. Vinks, and N. C. Punt. 1997. Pharmacokinetic- pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
51. Pamp, S. J., M. Gjermansen, H. K. Johansen, and T. Tolker-Nielsen. 2008. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 68:223-240.
52. Peyret, M., J. P. Flandrois, and G. Fardel. 1991. Time-killing curves of Pseudomonas aeruginosa strains exposed to polymyxin B. Pathol. Biol. (Paris) 39:446-450.
53. Piantieri, G., E. Magliulo, A. Cafarelli, G. Bossi, and M. Cruciani. 1981. Antibacterial activity in vitro of several aminoglycosides and cephalosporins. G. Batteriol. Virol. Immunol. 74:77-100. (In Italian.)
54. Roosendaal, R., I. A. Bakker-Woudenberg, M. van den Berghe-van Raffe, J. C. Vink-van den Berg, and M. F. Michel. 1991. Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur. J. Clin. Microbiol. Infect. Dis. 10:1019-1025.
55. Schindler, M., and M. J. Osborn. 1979. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18:4425-4430.
56. Schindler, P. R., and M. Teuber. 1975. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and in the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob. Agents Chemother. 8:95-104.
57. Schuster, M., and E. P. Greenberg. 2006. A network of networks: quorumsensing gene regulation in Pseudomonas aeruginosa. Int. J. Med. Microbiol. 296:73-81.
58. Schuster, M., C. P. Lostroh, T. Ogi, and E. P. Greenberg. 2003. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorumcontrolled genes: a transcriptome analysis. J. Bacteriol. 185:2066-2079.
59. Stearne, L. E., W. H. Goessens, J. W. Mouton, and I. C. Gyssens. 2007. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob. Agents Chemother. 51:3605-3611.
60. Stevens, D. L., S. Yan, and A. E. Bryant. 1993. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. 167:1401-1405.
61. Storm, D. R., K. S. Rosenthal, and P. E. Swanson. 1977. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46:723-763.
62. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, and M. V. Olson. 2000. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406:959-964.
63. Straus, S. K., and R. E. Hancock. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223.
64. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
65. Tam, V. H., A. N. Schilling, G. Vo, S. Kabbara, A. L. Kwa, N. P. Wiederhold, and R. E. Lewis. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3624-3630.
66. Treyaprasert, W., S. Schmidt, K. H. Rand, U. Suvanakoot, and H. Derendorf. 2007. Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int. J. Antimicrob. Agents 29:263-270.
67. Tsuji, B. T., and M. J. Rybak. 2005. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49:2735-2745.
68. Tsuji, B. T., C. von Eiff, P. A. Kelchlin, A. Forrest, and P. F. Smith. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-Colony-variant phenotype. Antimicrob. Agents Chemother. 52:1533-1537.
69. Tuomanen, E., and A. Tomasz. 1990. Mechanism of phenotypic tolerance of nongrowing pneumococci to beta-lactam antibiotics. Scand. J. Infect. Dis. Suppl. 74:102-112.
70. Udekwu, K. I., N. Parrish, P. Ankomah, F. Baquero, and B. R. Levin. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
71. Venkatesan, A., C. Spalding, A. Speedie, G. Sinha, and J. A. Rumbaugh. 2005. Pseudomonas aeruginosa infective endocarditis presenting as bacterial meningitis. J. Infect. 51:e199-e202.
72. Warren, H. S., S. A. Kania, and G. R. Siber. 1985. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 28:107-112.
73. Yang, J. C., J. B. Bulitta, A. Forrest, and B. T. Tsuji. 2007. High inocula Pseudomonas aeruginosa (PA) attenuates colistin bactericidal activity and alters pharmacodynamics (PD). Abstr. 47th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), poster A-6. American Society for Microbiology, Washington, DC.
74. Yohonn, L., S. V. Brown, J. B. Bulitta, A. Forrest, H. Sun, C. McPhee, P. N. Holden, P. A. Kelchlin, E. Dodds Ashley, C. E. Haas, D. Hardy, and B. T. Tsuji. 2007. Bactericidal activity of colistin against clinical isolates of Pseudomonas aeruginosa at high and low bacterial density, abstr. A-119. Abstr. 109th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.